Apellis Pharmaceuticals Stock Technical Analysis
| APLS Stock | USD 21.81 0.18 0.82% |
As of the 28th of January, Apellis Pharmaceuticals shows the mean deviation of 2.97, and Risk Adjusted Performance of (0.02). Apellis Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Apellis Pharmaceuticals market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Apellis Pharmaceuticals is priced correctly, providing market reflects its regular price of 21.81 per share. Given that Apellis Pharmaceuticals has information ratio of (0.06), we suggest you to validate Apellis Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.
Apellis Pharmaceuticals Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Apellis, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to ApellisApellis Pharmaceuticals' Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.Apellis Pharmaceuticals Analyst Consensus
| Target Price | Advice | # of Analysts | |
| 34.5 | Strong Buy | 22 | Odds |
Most Apellis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Apellis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Apellis Pharmaceuticals, talking to its executives and customers, or listening to Apellis conference calls.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.36 | Revenue Per Share | Quarterly Revenue Growth 1.33 | Return On Assets | Return On Equity |
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apellis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Apellis Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Apellis Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Apellis Pharmaceuticals.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in Apellis Pharmaceuticals on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding Apellis Pharmaceuticals or generate 0.0% return on investment in Apellis Pharmaceuticals over 90 days. Apellis Pharmaceuticals is related to or competes with Catalyst Pharmaceuticals, Kiniksa Pharmaceuticals, Mineralys Therapeutics, Beam Therapeutics, Adaptive Biotechnologies, Scholar Rock, and Ideaya Biosciences. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and ... More
Apellis Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Apellis Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Apellis Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 36.73 | |||
| Value At Risk | (4.69) | |||
| Potential Upside | 5.01 |
Apellis Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apellis Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Apellis Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Apellis Pharmaceuticals historical prices to predict the future Apellis Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.28) |
Apellis Pharmaceuticals January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.27) | |||
| Mean Deviation | 2.97 | |||
| Coefficient Of Variation | (2,262) | |||
| Standard Deviation | 5.22 | |||
| Variance | 27.23 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.28) | |||
| Maximum Drawdown | 36.73 | |||
| Value At Risk | (4.69) | |||
| Potential Upside | 5.01 | |||
| Skewness | (3.41) | |||
| Kurtosis | 18.96 |
Apellis Pharmaceuticals Backtested Returns
Currently, Apellis Pharmaceuticals is not too volatile. Apellis Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0416, which signifies that the company had a 0.0416 % return per unit of standard deviation over the last 3 months. We have found twenty-three technical indicators for Apellis Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please confirm Apellis Pharmaceuticals' mean deviation of 2.97, and Risk Adjusted Performance of (0.02) to double-check if the risk estimate we provide is consistent with the expected return of 0.15%. Apellis Pharmaceuticals has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.87, which signifies possible diversification benefits within a given portfolio. Apellis Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Apellis Pharmaceuticals is expected to follow. Apellis Pharmaceuticals right now shows a risk of 3.62%. Please confirm Apellis Pharmaceuticals total risk alpha, as well as the relationship between the skewness and day median price , to decide if Apellis Pharmaceuticals will be following its price patterns.
Auto-correlation | -0.63 |
Very good reverse predictability
Apellis Pharmaceuticals has very good reverse predictability. Overlapping area represents the amount of predictability between Apellis Pharmaceuticals time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Apellis Pharmaceuticals price movement. The serial correlation of -0.63 indicates that roughly 63.0% of current Apellis Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.63 | |
| Spearman Rank Test | -0.25 | |
| Residual Average | 0.0 | |
| Price Variance | 4.39 |
Apellis Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Apellis Pharmaceuticals Technical Analysis
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Apellis Pharmaceuticals volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About Apellis Pharmaceuticals Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Apellis Pharmaceuticals on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Apellis Pharmaceuticals based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Apellis Pharmaceuticals price pattern first instead of the macroeconomic environment surrounding Apellis Pharmaceuticals. By analyzing Apellis Pharmaceuticals's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Apellis Pharmaceuticals's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Apellis Pharmaceuticals specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2023 | 2024 | 2025 | 2026 (projected) | Days Sales Outstanding | 190.0 | 126.93 | 145.97 | 182.59 | PTB Ratio | 36.52 | 17.3 | 15.57 | 16.25 |
Apellis Pharmaceuticals January 28, 2026 Technical Indicators
Most technical analysis of Apellis help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Apellis from various momentum indicators to cycle indicators. When you analyze Apellis charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.27) | |||
| Mean Deviation | 2.97 | |||
| Coefficient Of Variation | (2,262) | |||
| Standard Deviation | 5.22 | |||
| Variance | 27.23 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.28) | |||
| Maximum Drawdown | 36.73 | |||
| Value At Risk | (4.69) | |||
| Potential Upside | 5.01 | |||
| Skewness | (3.41) | |||
| Kurtosis | 18.96 |
Apellis Pharmaceuticals January 28, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Apellis stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 92,498 | ||
| Daily Balance Of Power | (0.18) | ||
| Rate Of Daily Change | 0.99 | ||
| Day Median Price | 21.60 | ||
| Day Typical Price | 21.67 | ||
| Price Action Indicator | 0.12 |
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.